

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

**RU-0175**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/009054

PRIORITY DATE CLAIMED

8 June 1999

INTERNATIONAL APPLICATION NO  
PCT/US00/15783

INTERNATIONAL FILING DATE  
8 June 2000

**TITLE OF INVENTION**

# COMPOSITIONS AND METHODS FOR TARGETED GENE INSERTION

APPLICANT(S) FOR DO/EO/US  
LAM, Eric

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☒ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

- 1) Courtesy copy of the International Application;
- 2) Return post card.

ATTORNEY'S DOCKET NUMBER

RU-0175

24. The following fees are submitted:

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :**

- |                                     |   |           |
|-------------------------------------|---|-----------|
| <input type="checkbox"/>            | Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO | \$1040.00 |
| <input type="checkbox"/>            | International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO   | \$890.00  |
| <input type="checkbox"/>            | International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO  | \$740.00  |
| <input checked="" type="checkbox"/> | International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)   | \$710.00  |
| <input type="checkbox"/>            | International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)   | \$100.00  |

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**\$710.00**

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	36 - 20 =	16	x \$18.00	\$288.00
Independent claims	1 - 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable).				\$280.00

Multiple Dependent Claims (check if applicable)

**\$280.00**

**TOTAL OF ABOVE CALCULATIONS** =

**\$1,278.00**

- ☒ Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

**\$639.00**

**SUBTOTAL** =

**\$639.00**

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

**\$639.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

**\$0.00**

**TOTAL FEES ENCLOSED**

**\$639.00**

Amount to be:
refunded
charged

- a. ☐ A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-1619 in the amount of \$639.00 to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1619. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:**

**Jane Massey Licata, Registration No. 32,257**  
**Kathleen A. Tyrrell, Registration No. 38,350**  
**Licata & Tyrrell P.C.**  
**66 East Main Street**  
**Marlton, New Jersey 08053**

**Tel:** 856-810-1515  
**Fax:** 856-810-1454

SIGNATURE

**Jane Massey-Licata**

NAME \_\_\_\_\_

32,257

REGISTRATION NUMBER

**December 6, 2001**

DATE: \_\_\_\_\_

Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
International  
Application No.: PCT/US00/15783  
U.S. Serial No.: N/A  
International  
Filing Date: Herewith  
Title: Compositions and Methods for Targeted  
Gene Insertion

"Express Mail" Label No. EV017477770US  
Date of Deposit : December 6, 2001

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
U.S. Patent and Trademark Office, PO Box 2327, Arlington,  
VA 22202.

By Jane Massey Licata  
Jane Massey Licata, Registration No. 32,257

U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Box: PCT

Dear Sir:

PRELIMINARY AMENDMENT

Please enter the following amendment and remarks into the  
record:

Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
Application No.: PCT/US00/15783  
Page 2

In the claims:

Please amend the claims as follows:

Beginning at page 32, line 16, with the following:

25.(amended) A method for inserting a heterologous DNA molecule into a pre-determined location on a plant genome, which comprises;

a) transforming a sample of plant cells containing the genome with the DNA construct of Claim 24, to produce a substrate-transformed cell line;

b) transforming an equivalent sample of plant cells with a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct of claim 24, to produce a transposase-transformed cell line;

c) regenerating fertile organisms from each of the transformed cell lines;

d) crossing the substrate-transformed line with the transposase-transformed line to produce F1 progeny;

e) self-pollinating the F1 progeny to produce F2 progeny; and

f) growing the F2 progeny in the presence of the positive selection agent and the negative selection agent, progeny

Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
Application No.: PCT/US00/15783  
Page 3

plants comprising the heterologous DNA inserted into the pre-determined location on the plant's genome being capable of surviving in the presence of both the positive selection agent and the negative selection agent.

Beginning at page 33, line 7, with the following:

26.(amended) The method of Claim 25, which further comprises selecting a substrate-transformed cell line comprising one copy of the DNA construct per cell.

Beginning at page 33, line 11, with the following:

28.(amended) The kit of claim 27, which further comprises a DNA construct having a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct.

Beginning at page 33, line 23, with the following:

29.(amended) A method for activation tagging of a plant genome to create variants displaying a desired phenotype, which comprises:

a) transforming a sample of plant cells containing the genome with the DNA construct of claim 1 or claim 24, to produce a substrate-transformed cell line;

Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
Application No.: PCT/US00/15783  
Page 4

b) transforming an equivalent sample of plant cells with a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct of claim 1, to produce a transposase-transformed cell line;

c) regenerating fertile organisms from each of the transformed cell lines;

d) crossing the substrate-transformed line with the transposase-transformed line to produce F1 progeny;

e) self-pollinating the F1 progeny to produce F2 progeny; and

f) growing the F2 progeny under conditions pre-determined to select for the desired phenotype in the plant.

Beginning at page 34, line 23, with the following:

32.(amended) The kit of claim 31, which further comprises a DNA construct having a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct.

#### REMARKS

This Preliminary Amendment is being filed to correct inadvertent typographical errors in claims 25, 26, 28, 29 and 32. Support for these amendments is found throughout the specification and especially at pages 32 through 34 of the specification. No new

Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
Application No.: PCT/US00/15783  
Page 5

matter has been added by this amendment. Entry of this amendment is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: December 6, 2001

LICATA & TYRRELL P.C.  
66 E. Main Street  
Marlton, NJ 08053  
(856) 810-1515

Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
Application No.: PCT/US00/15783  
Page 6

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

The claims have been amended as follows:

25.(amended) A method for inserting a heterologous DNA molecule into a pre-determined location on a plant genome, which comprises;

a) transforming a sample of plant cells containing the genome with the DNA construct of Claim 24, to produce a substrate-transformed cell line;

b) transforming an equivalent sample of plant cells with a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct of claim 24, to produce a transposase-transformed cell line;

b)c) regenerating fertile organisms from each of the transformed cell lines;

c)d) crossing the substrate-transformed line with the transposase-transformed line to produce F1 progeny;

d)e) self-pollinating the F1 progeny to produce F2 progeny; and



Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
Application No.: PCT/US00/15783  
Page 7

e)f) growing the F2 progeny in the presence of the positive selection agent and the negative selection agent, progeny plants comprising the heterologous DNA inserted into the predetermined location on the plant's genome being capable of surviving in the presence of both the positive selection agent and the negative selection agent.

26.(amended) The method of Claim ~~26~~ 25, which further comprises selecting a substrate-transformed cell line comprising one copy of the DNA construct per cell.

28.(amended) The kit of claim 27, which further comprises a DNA construct having a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct. ~~of claim 27.~~

29. (amended) A method for activation tagging of a plant genome to create variants displaying a desired phenotype, which comprises:

a) transforming a sample of plant cells containing the genome with the DNA construct of claim 1 or claim 24, to produce a substrate-transformed cell line;

b) transforming an equivalent sample of plant cells with a gene encoding a transposase that specifically acts on the

Attorney Docket No.: RU-0175  
Inventors: Eric Lam  
Application No.: PCT/US00/15783  
Page 8

DNA substrates in the DNA construct of claim 1, to produce a transposase-transformed cell line;

~~b) c)~~ regenerating fertile organisms from each of the transformed cell lines;

~~c) d)~~ crossing the substrate-transformed line with the transposase-transformed line to produce F1 progeny;

~~d) e)~~ self-pollinating the F1 progeny to produce F2 progeny; and

~~e) f)~~ growing the F2 progeny under conditions pre-determined to select for the desired phenotype in the plant.

32. The kit of claim ~~32~~ 31, which further comprises a DNA construct having a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct. ~~of claim 31.~~

COMPOSITIONS AND METHODS FOR  
TARGETED GENE INSERTION

This application claims priority to U.S. Provisional Application No. 60/138,968, Filed June 8, 1999, the entirety of which is incorporated by reference herein.

5

**FIELD OF THE INVENTION**

This invention relates to the field of molecular biology and manipulation of the eucaryotic genome. In particular, the invention provides a novel system and DNA constructs for integrating heterologous DNA segments at selected locations in target genomes.

10

**BACKGROUND OF THE INVENTION**

Various scientific articles are referred to in parentheses throughout the specification, and complete citations are listed at the end of the specification. These articles are incorporated by reference herein to describe the state of the art to which this invention pertains.

15

The ability to create a null mutation in a specific gene can provide an unambiguous test of the functional role of its gene product in an organism. Creating a null mutation has obvious advantages over approaches utilizing antisense transcripts since null mutations do not present problems such as incomplete suppression of the target gene product and unknown specificity of its effects. In addition, the dominant nature of the antisense approach for gene suppression is one major drawback. Thus, if the gene of interest is critical for survival or fitness of the organism, one may inadvertently select against transformants that have

20

25

30

effectively "shut down" the expression of the target gene. Alternatively, one may select for spontaneous second site mutations that compensate for the defect caused by the gene suppression. In contrast, the  
5 recessive nature of targeted gene insertion via homologous recombination should avoid these concerns. The first targeted progeny should be in the heterozygous state and in most cases, a wild-type phenotype would be expected. The phenotype(s) caused by the loss of the  
10 targeted gene can be studied in the homozygous progenies of subsequent generations. In this way, even housekeeping genes that are essential can be studied as embryo lethals.

Another type of reverse genetics approach is  
15 the so-called "gene machine" screens, in which a large collection of random T-DNA or transposon integration events are screened by PCR to identify insertions in or near the locus of interest (1, 4, 6). Although this technique has been successful in the identification of  
20 insertion mutations for genes of interest, a routine gene targeting approach should be more versatile in the directed mutagenesis of specific genes. For example, approaches such as gene swapping, the so-called "knock-in" mutation, or any other precise alterations at the  
25 locus of interest are not possible with the "gene machine" approach.

Although gene targeting has become a well-defined technique in mouse research (2), the specific disruption of a non-selectable locus in higher plants has  
30 not been reported until recently. Most of the earlier work on gene targeting in higher plants involved the repair/mutation of a selectable marker gene (8-10). The observed frequencies of recombination using that method were invariably low (9).

35 For ectopic expression studies in which a

For commercial purposes, specific manipulation of the genome through gene targeting should also greatly facilitate the process of registration for the transgenic materials. At the present time, clinical trials to demonstrate the safety of transgenic crops are needed for any new transgenic plant materials to be released as commercial products. One of the major reasons for this requirement is to safeguard against production of allergens or toxins in new transgenic lines that may result from inadvertent mutations due to random insertion events. Targeted gene insertion would obviate this concern and thus result in substantial savings of time and resources for this phase of product commercialization.

One approach to targeting employed a general gene-targeting construct using a kanamycin resistance gene (*NptII*) as a positive selection marker (7). Polylinkers were designed in the flanking regions of this marker to facilitate the cloning of genomic fragments from the target of interest. To facilitate detection of illegitimate insertion events, a GUS expression unit, which is a screenable marker, was inserted outside of the homologous regions. In the event of a double cross-over

Despite the obvious value of targeting  
30 mutations to specific, selected locations within the  
genome, sometimes it is yet desirable to screen for  
particular phenotypes among a population of random  
mutations. The method of activation tagging (14, 15) for  
creating random mutants has proven valuable. The method  
35 involves tagging genes at random by the insertion of DNA

- 5 -

constructs comprising a selection marker gene and transcriptional promoters which are able to transactivate the expression of genes in the vicinity of the insertion. The result is the generation of dominant mutants which  
5 survive in the presence of the selection agent and which have been useful in studying genetic influences on plant growth substances, polyamine metabolism, signal transduction by cytokines and abscisic acid, for example. The method retains the disadvantage of requiring large  
10 numbers of transformants which precludes application to many agronomically important plants.

#### SUMMARY OF THE INVENTION

The present invention provides a new process  
15 and new DNA constructs and vectors for targeted manipulation of eucaryotic genomes. One key feature of this novel approach for gene targeting is the generation of recombinant substrates through the deployment of transposable elements. In a preferred embodiment, it  
20 provides a key advantage by minimizing the number of recombination substrates to one per cell. Among other advantages of the approach, it solves two general problems associated with currently available methods. First, it minimizes the number of independent  
25 transformation events required to obtain the infrequent homologous recombination events rather than the more frequent random integration events. This enables the application of gene targeting technologies to more organisms of interest. Second, the novel deployment of  
30 powerful negative selection strategies streamlines the recovery of low-frequency homologous recombination events by suppressing or eliminating complex integration processes.

According to one aspect of the invention, a  
35 general DNA construct for producing a gene targeting

- 6 -

construct is provided. The DNA construct is bounded by termini within which are a pair of DNA substrates for a selected transposase. These DNA substrates contain between them the following elements: (1) a first cloning  
5 site and a second cloning site for insertion of one or more additional DNA segments, wherein the first cloning site and the second cloning site have disposed between them a positive selection gene encoding a gene product that confers to the cells a selectable phenotype  
10 comprising resistance to a positive selection agent that is deleterious or lethal to cells having genomes in which the DNA construct has not integrated; and (2) a negative selection gene disposed between one of the DNA substrates for the selected transposase and either the first cloning  
15 site or the second cloning site, but not between the first cloning site and the second cloning site, the negative selection gene conferring to the cells a selectable phenotype comprising susceptibility to a negative selection agent, to which cells having genomes  
20 in which the DNA construct has not integrated are not susceptible. Optionally, the DNA construct contains a detectable marker gene encoding a detectable gene product. The detectable marker gene is operably inserted in the DNA construct relative to one of the DNA  
25 substrates for the selected transposase such that, upon excision of the DNA construct from a genome by the action of the transposase, the detectable gene product is no longer detectable. Preferably, the detectable marker gene is inserted in the construct such that one of the  
30 DNA substrates for the selected transposase is located within the gene, between its promoter and coding sequence.

The DNA construct described above can be used for random insertion of a gene of interest into a genome.  
35 In accordance with a significant aspect of the invention,





- 8 -

crossed with a line that expresses the transposase specific for the DNA substrates engineered into the vector (if created recombinantly, then referred to as a "transposase-transformed" line), to produce heterozygous F1 progeny. The progeny contain the transposase and the transforming DNA construct harboring the transposase recognition sites. Excision and integration events occur naturally in these hybrid plants as they grow, due to the presence of the transposase and its substrate. Since the F1 hybrids are heterozygous, excision at the DNA substrate sites on the construct occurs which releases a portion of the transforming DNA, referred to as the "recombination substrate". In a preferred embodiment the excision will generate, per cell, a single copy of the "recombination substrate". The recombination substrate contains the targeting segment with the positive selection gene, as well as the negative selection gene located outside the targeting segment.

Step 3. The F1 plants are allowed to self-pollinate to produce F2 seed. Optionally, this step may be carried forward into the F3 and subsequent generations. Seeds are germinated on growth media containing the positive and negative selection agents. Random integration of the recombination substrate into the genome results in plants that are sensitive to the negative selection agent and resistant to the positive selection agent. However, integration of the excised insert by double crossover events at the targeted locus results in plants that are resistant both to the negative selection agent and to the positive selection agent. These plants may be selected and/or maintained by their ability to survive in the presence of both selection agents, while plants containing random integrants cannot survive on the negative selection agent.

35           According to another aspect of the invention,

- 9 -

the aforementioned DNA constructs and methods may be adapted to perform activation tagging of a plant genome to create variants displaying a desired phenotype. In this case, the selection step for the progeny omits the  
5 negative selection. Instead, the plants are screened for the phenotype desired to be identified by the activation tagging method.

According to another aspect of the invention, kits are provided to facilitate performance of the  
10 targeted gene insertion or activation tagging methods described above. The kits provide one or more of the DNA constructs of the invention, along with instructions for their use in performing the methods.

15 Other features and advantages of the present invention will be better understood by reference to the drawings, detailed description and examples that follow.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 **Figure 1.** Generalized *Agrobacterium*-based gene targeting construct. RB, Right border; LB, Left border; PLS1, polylinker sequence 1; PLS2, polylinker sequence 2; *CodA*, cytosine deaminase-encoding sequence; *Bar*, phosphinothricin acetyltransferase-encoding sequence;  
25 *GUS*,  $\beta$ -glucuronidase-encoding sequence; 35S, CaMV 35S promoter; nos, 3' polyadenylation sequence from the nopaline synthase gene; *Ds*, excision target (DNA substrate) for the *Ac*-dependent transposase.

**Figure 2.** Strategy for *Ac*-dependent production  
30 of recombination substrates *in planta* for gene targeting. The *Arabidopsis* gene *TGA3* is used as an example to illustrate the use of *Ac*-dependent excision to generate substrates for recombination. The hatched regions designate genome sequences flanking *TGA3* and are cloned

- 10 -

into the polylinker sites (PLS1, PLS2) of the targeting construct as shown in Figure 1. Homozygous transgenic plants containing this insert are crossed with a line that is expressing the Ac transposase (35S:Ac/*NptII*).

- 5   Excision at the *Ds* sites of the transgene releases a single molecule of the recombination substrate. Random reintegration of the excised insert produces plants that are 5-Fc<sup>+</sup>, PPT<sup>r</sup>, and GUS<sup>-</sup> while the parental line is 5-Fc<sup>+</sup>, PPT<sup>r</sup>, and GUS<sup>-</sup>. However, integration of the excised
- 10   insert via double cross-over events at the *TGA3* locus will result in plants that are 5-Fc<sup>+</sup>, PPT<sup>r</sup>, and GUS<sup>-</sup>. These can be confirmed by performing PCR with genomic DNA using the diagnostic primers P1 and P2, as indicated. The heterozygous nature of the primary targeted
- 15   transformant is illustrated on the bottom by showing the wild-type *TGA3* allele along with the targeted allele.

## DETAILED DESCRIPTION OF THE INVENTION

### I. Definitions

- 20       Various terms relating to the biological molecules and other aspects of the present invention are used throughout the specification and claims.

- With reference to the mutations of the invention, the term "null mutant" is used to designate an
- 25   alteration in the genomic DNA sequence of an organism that can cause the product or function of the gene to be largely absent or nonfunctional. Such alterations may occur in coding and/or noncoding regions of the gene, including regulatory regions or other regions which when
- 30   altered cause said product or function to be largely absent or nonfunctional. The alterations may include insertions and/or deletions of one or more base pairs and/or changes in one or more base pairs.

- In reference to the strategic placement of
- 35   heterologous DNA segments within the genomic DNA, the



1000906-4 - 942906

oligonucleotide, protein, etc.). More preferably, the preparation comprises at least 75% by weight, and most preferably 90-99% by weight, the compound of interest. Purity is measured by methods appropriate for the compound of interest (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like).

Nucleic acid sequences and amino acid sequences can be compared using computer programs that align the similar sequences of the nucleic or amino acids thus define the differences. In preferred methodologies, the BLAST programs (NCBI) and parameters used therein are employed, and the DNASTAR system (Madison, WI) is used to align sequence fragments of genomic DNA sequences. However, equivalent alignments and similarity/identity assessments can be obtained through the use of any standard alignment software. For instance, the GCG Wisconsin Package version 9.1, available from the Genetics Computer Group in Madison, Wisconsin, and the default parameters used (gap creation penalty=12, gap extension penalty=4) by that program may also be used to compare sequence identity and similarity.

The terms "percent identical" and "percent similar" are also used herein. When referring to nucleic acid molecules, "percent identical" refers to the percent of the nucleotides of the subject nucleic acid sequence that have been matched to identical nucleotides by a sequence analysis program.

With respect to single-stranded nucleic acid  
30 molecules, the term "specifically hybridizing" refers to  
the association between two single-stranded nucleic acid  
molecules of sufficiently complementary sequence to  
permit such hybridization under pre-determined conditions  
generally used in the art (sometimes termed  
35 "substantially complementary"). In particular, the term

- 14 -

refers to hybridization of an oligonucleotide with a substantially complementary sequence contained within a single-stranded DNA or RNA molecule, to the substantial exclusion of hybridization of the oligonucleotide with  
5 single-stranded nucleic acids of non-complementary sequence.

A "coding sequence" or "coding region" refers to a nucleic acid molecule having sequence information necessary to produce a gene product, when the sequence is  
10 expressed.

The term "operably linked" or "operably inserted" means that the regulatory sequences necessary for expression of the coding sequence are placed in a nucleic acid molecule in the appropriate positions  
15 relative to the coding sequence so as to enable expression of the coding sequence. This same definition is sometimes applied to the arrangement other transcription control elements (e.g. enhancers) in an expression vector.

20 Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

25 The terms "promoter", "promoter region" or "promoter sequence" refer generally to transcriptional regulatory regions of a gene, which may be found at the 5' or 3' side of the coding region, or within the coding region, or within introns. Typically, a promoter is a  
30 DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. The typical 5' promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5'  
35 direction) to include the minimum number of bases or



- 15 -

elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence is a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A "vector" is a replicon, such as plasmid, phage, cosmid, or virus to which another nucleic acid segment may be operably inserted so as to bring about the replication or expression of the segment.

The term "nucleic acid construct" or "DNA construct" is sometimes used to refer to a coding sequence or sequences operably linked to appropriate regulatory sequences and inserted into a vector for transforming a cell. This term may be used interchangeably with the term "transforming DNA". Such a nucleic acid construct may contain a coding sequence for a gene product of interest, along with a selectable marker gene and/or a reporter gene.

The terms "selectable marker gene" or "selection marker gene" refer to a gene encoding a product that, when expressed, confers a selectable phenotype on a transformed cell. "Positive selection marker" refers to a gene whose functioning gene product, when expressed, confers upon a cell the phenotype of survival or growth in the presence of a positive selection agent which is deleterious or lethal to cells which do not possess the "positive selection marker". "Negative selection marker" refers to a gene whose functioning gene product, when expressed, confers upon a cell the phenotype of susceptibility to the presence of a negative selection agent to which cells which do not possess the "negative selection marker" are not susceptible.

The term "reporter gene" or "detectable marker

A "heterologous" region of a nucleic acid construct is an identifiable segment (or segments) of the nucleic acid molecule within a larger molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, a heterologous region is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein. The term "DNA construct", as defined above, is also used to refer to a heterologous region, particularly one constructed for use in transformation of a cell.

A cell has been "transformed" or "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A

- 17 -

"clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

5 Other definitions may be found in the description that follows.

## II. Description

To practice the novel gene targeting strategy  
 10 of the present invention, a DNA construct for transforming cells is needed that has, combined in novel fashion, the following elements: (1) targeting segments that comprise extended regions of homology with the targeted location on the genome; (2) a positive selection  
 15 gene contained between appropriate targeting segments; (3) a negative selection gene located outside the targeting segments; and (4) a pair of DNA substrates for a selected transposase, located outside the targeting segments and the negative selection gene. Optionally,  
 20 the region between the targeting segments may also contain one or more cloning sites for insertion of additional nucleotide sequences. In addition, the transforming DNA construct optionally may contain a reporter gene which, if present, preferably has disposed  
 25 therewithin one of the transposase recognition sites, such that upon excision, the activity of the reporter gene product is not detectable. In a preferred embodiment, the DNA substrate is located between the promoter sequence and the gene sequence encoding the  
 30 reporter gene product, such that upon excision and reintegration, the intact promoter remains nears one of the ends of the integrated DNA. In another preferred embodiment, the DNA substrate is short (<1.5 Kb) such that it still retains the specific recognition sites for  
 35 the transposase, but does not interfere with the ability

of the promoter to drive expression of the reporter gene activity.

The targeting segment is a DNA sequence that has homology with a selected region of the genome being transformed, and which is of sufficient length and homology to ensure the homologous recombination event necessary for incorporation of the transforming DNA into the genome. The targeting segment may comprise regions of homology that encompass or flank the selected target region of the genome. The targeting segments are preferably greater than 500 bases on either side of the positive selection gene and optional additional nucleotide segments. More preferably, they are greater than about 1 kb to 1.5 kb on either side of the positive selection gene, and most preferably they are at least 2-3 kb on either side of the positive selection gene. One skilled in the art will be able to determine the required length of the targeting sequences by considering the relative factors of length and relative homology with the known or anticipated sequence of the targeted genomic sequence, the critical factor being that the selected targeting sequence allow for the low frequency event of homologous recombination. For example, it would be appreciated by one skilled in the art that the targeting sequence could be shorter in cases where there is a high degree of similarity or identity with the targeted genomic sequence, or that the targeting sequence might be longer in the case of low similarity or where the sequence of targeted genomic DNA is not fully known.

The targeting segments can be selected for homologous recombination with any portion of a genome of interest. Preferably, however, genome targets comprising genes or regulatory regions are selected. Alternatively, regions adjacent to or near genes may be selected, such that insertions may be made without disrupting gene

expression.

The positive selection gene may comprise one of many such genes known and used in the art. Useful selectable marker systems include, but are not limited to: genes that confer antibiotic resistances (e.g., resistance to kanamycin, hygromycin or bialaphos) or herbicide resistance (e.g., resistance to sulfonylurea, phosphinothricin, or glyphosate). In the preferred embodiment taught in Example 1, the *Bar* gene, which confers resistance to herbicides that are based on phosphinothricin (PPT), is utilized.

The negative selection gene also may be one of several such genes known in the art. Preferred for use in the invention is the *CodA* gene, encoding cytosine deaminase. This enzyme converts the innocuous 5-fluorocytosine to the cytotoxic 5-fluorouracil. Other negative selections that can be used in the invention include, but are not limited to, the *aux-2* gene from the Ti-plasmid of *Agrobacterium*, the *TK* gene from SV40, cytochrome *f450* from *Streptomyces griseolus*, the *Adh* gene from maize or *Arabidopsis*, or any gene encoding an enzyme capable of converting innocuous substances into harmful or lethal substances.

The strategies of the present invention can be used in any system known now or discovered in the future to harbor transposable element systems. The present invention exemplifies gene targeting in plants using the well-characterized *Ac/Ds* system. Other plant transposable element systems suitable for use in the present invention include, but are not limited to: *Spm(En)/dSpm* from maize, *Dt/rdt* from maize, *Mu-MI/Mn* from maize, and *Tam1/Tam2* or *Tam3/Tam4* from snapdragon. The *P* element from *Drosophila melanogaster* is also suitable for use in the present invention. Persons skilled in the art

- 20 -

will appreciate that numerous other organisms, including *Drosophila*, yeast, the nematode, *C. elegans*, and mammals such as mice, contain characterized transposable element systems, each of which has potential for use in the present invention.

The optional detectable marker gene may be selected from any of the numerous genes known and used in the art for this purpose. Examples of suitable detectable marker genes include, but are not limited to, genes encoding:  $\beta$ -glucuronidase (GUS),  $\beta$ -galactosidase, chloramphenicol acetyl transferase (CAT), various transcription factors, alcohol dehydrogenase and luciferase. In the preferred embodiment taught in Example 1, the GUS marker is utilized.

The above-described DNA constructs may be used directly or as part of a vector, in accordance with the wide variety of transformation methods available to persons of skill in the art.

In one preferred embodiment, the gene targeting strategy of the invention is applied to plants. Transgenic plants can be generated using standard plant transformation methods known to those skilled in the art. These include, but are not limited to, biolistic DNA delivery (i.e., particle bombardment), *Agrobacterium* vectors, PEG treatment of protoplasts, UV laser microbeam, gemini virus vectors, calcium phosphate treatment of protoplasts, electroporation of isolated protoplasts, agitation of cell suspensions with microbeads coated with the transforming DNA, direct DNA uptake, liposome-mediated DNA uptake, and the like. Such methods have been published in the art. See, e.g., Methods for Plant Molecular Biology (Weissbach & Weissbach, eds., 1988); Methods in Plant Molecular Biology (Schuler & Zielinski, eds., 1989); Plant Molecular Biology Manual (Gelvin, Schilperoort, Verma,

- 21 -

eds., 1993); and Methods in Plant Molecular Biology - A Laboratory Manual (Maliga, Klessig, Cashmore, Gruissem & Varner, eds., 1994).

5 The method of transformation depends upon the plant to be transformed. The biolistic DNA delivery method is useful for nuclear transformation of monocotyledenous plants, such as maize. Alternatively, *Agrobacterium* vectors, particularly superbinary vectors such as described by Ishida et al. (Nature Biotechnology 10 14:745-750, 1996) are used for transformation of plant nuclei.

In another embodiment, the DNA constructs of the invention are used for activation tagging of plants. After transformation using standard plant transformation 15 methods known to those skilled in the art, selection with the positive selection agent, but not the negative selective agent will allow the higher frequency random integration events to be recovered as well as other transformants. These transformants will also have 20 detectable amounts of reporter gene product activity. Transgenic plants are then regenerated from these transformants and these plants are then crossed with lines expressing the transposase activity corresponding to the DNA substrates of the transforming DNA vectors. 25 The active transposition of the integrated DNA will result in progeny with insertions in many different locations throughout the genomic DNA. These progeny will often contain genes which are being overexpressed due to transactivation by a promoter in the integrated DNA which 30 transactivates downstream gene expression. This population of transformed and transposed mutants or its progeny can then be screened for useful phenotypes. For plants of agronomic interest, this method of activation tagging has substantial advantages over current methods 35 in that only small numbers of independent transformants

- 22 -

are required, yet the novel application of the transposable element system enables the possibility of a large population of potential mutations. In a preferred embodiment of this method, the DNA substrate of the DNA construct is inserted in the reporter gene between the promoter sequence and the encoding sequence such that upon excision, the promoter will be close to one end of the excised and reintegrated DNA, and the detectable activity of the reporter gene will be largely absent or nondetectable. In a still more preferred embodiment of this method, the DNA substrate used is a short (<1.5 kb) Ds element from maize. Without intending to limit the invention in any way by explanation, presumably longer Ds elements contain transcription termination signals which would interfere with the expression of both the reporter gene as well as any transactivated genes. In a highly preferred embodiment, the multiple copies of a promoter are used or promoter(s) with inducible activity or tissue-specific activity or other such promoters as would be known to one skilled in the art to be useful. In another preferred embodiment, seed can be collected from the transformed and transposed population or its progeny to be used for screening for useful phenotypes.

The following example is provided to describe the invention in greater detail. It is intended to illustrate, not to limit, the invention.

#### EXAMPLE 1

##### **Transposon-Based Gene Targeting Strategy for Plants, Using *Agrobacterium* Vectors**

This example describes new DNA targeting constructs to facilitate the transfer of gene targeting technology from *Arabidopsis* to crop plants such as maize. The new construct design comprises a more general





- 24 -

gene provides negative selection during seed germination and early seedling growth in the presence of 5-fluorocytosine (5-Fc) [11, 13]. This construct was tested in *Arabidopsis* and was found to provide good negative selection on agar plates supplemented with 5-Fc (Figure 4), as reported earlier by other researchers. Incorporation of the *CodA* expression cassette into the targeting construct is intended to help to minimize the number of random insertion events.

3) **Application of a transposon-based gene targeting strategy.** Although, in principle, the inclusion of a negative selection marker should simplify the gene targeting approach, it may not be compatible with the preferred *Agrobacterium*-mediated transformation method. With *Agrobacterium*-based plant transformation strategies, multiple copies of the T-DNA are often inserted in the genome of transformed plant cells. In this case, the targeted event may coexist with random insertions and is removed when negative selection is applied (5, 13).

To avoid this problem, one solution is to devise a method to limit the substrate for recombination to one copy per cell. This should then rule out the possibility of having multiple insertion events, through either illegitimate or homologous recombination. To accomplish this, the *Ac/Ds* transposon system is employed as an *in planta* generator of integration substrates (12). This is described in more detail in the following section.

In addition to solving the problem of multiple integration events, this approach also broadens the application of gene targeting to other plant species. A major obstacle in applying gene targeting to agronomically important species, such as maize and rice,

is the difficulty in generating a large number of independent transformants (in the order of 1,000). Novel use of a transposon-based gene targeting method eliminates this difficulty.

## Experimental Approach

The experimental design utilizes a known genomic target in *Arabidopsis*. The general targeting construct shown in Figure 1 is constructed, using standard cloning and DNA manipulation methods. As shown in Figure 1, the *CodA* gene is placed upstream of the polylinker region, into which can be inserted the genomic sequence for targeting. For DNA excision, short (<1.5 kb) Ds elements are placed next to the Right Border and within the 35S-GUS cassette. With this configuration of the construct, the frequency of excision can be assayed by measuring the loss of GUS activity, since this loss results in white sectors upon staining with X-Gluc. The *Bar* gene, flanked by the inserted genomic sequences, provides the positive selection marker for the insertion event. After construction of this vector, *Arabidopsis* genomic sequences from TGA3 are inserted into the polylinker sites (Fig 1, PLS1 and PLS2). Transformation of *Arabidopsis* via *Agrobacterium* is carried out and the transgenic lines are selected on PPT-containing plates.

These PPT-resistant plants, but not the wild-type, are also sensitive to 5-Fc, due to *CodA* expression. In addition, they have high levels of GUS activity (Figure 2, step 1). Ten to twenty transformed lines that show these characteristics are evaluated by Southern blot analysis to determine the copy number of the inserted T-DNA. Several transformed lines with single copy insertions are self-pollinated to produce homozygous plants. They are then crossed with another homozygous

- 26 -

*Arabidopsis* line that expresses the stablized *Ac* transposase (12). This activates the excision of the sequences in the original construct that are flanked by the two *Ds* elements (Figure 2, step 2). The efficiency of excision in the F1 progenies is verified by staining the leaves with X-Gluc. Cells that have activated *Ds* transposition are white while the other cells are blue. The excised DNA can be reinserted randomly in the genome, in which case the *CodA* gene is retained (Figure 2, excised insert). Alternatively, if the insertion occurs via homologous recombination at the two homology regions, then this marker is lost. The selection scheme entails screening the F2 or F3 progenies on medium containing 5-Fc and PPT. The surviving plants are then subjected to a secondary screen to confirm the loss of the GUS marker. The predicted genome structure and phenotypes of the targeted event are shown at the bottom of Figure 2. Plants recovered after these screens are analyzed via PCR using diagnostic primers (shown as P1 and P2 in Figure 2) that specifically detect the desired targeted event (7). Southern blots are performed to confirm the proper integration of the *Bar* gene into the *TGA3* locus.

#### REFERENCES

- 1) Bensen RJ, Johal GS, Crane VC, Tossberg JT, Schnable PS, Meeley RB and Briggs SP (1995) **Plant Cell** 7: 75-84.
- 2) Capecchi MR (1989) **Science** 244: 1288-1292.
- 3) Kempin SA, Liljegren SJ, Block LM, Rounsley SD, Yanofsky MF and Lam E (1997) **Nature** 389: 802-803.
- 4) Krysan PJ, Young JC, Tax F and Sussman MR (1996) **Proc. Natl. Acad. Sci. USA** 93: 8145- 8150.
- 5) Liljegren SJ and Yanofsky MF (1998) **Trends in Plant Sci.** 3: 79-80.

- 27 -

- 6) McKinney EC, Ali N, Traut A, Feldmann KA, Belostotsky DA, McDowell JM and Meagher RB (1995) **Plant J.** 8: 613-622.
- 7) Miao Z-H and Lam E (1985) **Plant J.** 7: 359-365.
- 8) Paszkowski J, Baur M, Bogucki A and Potrykus I (1988) **EMBO J.** 7: 4021-4026.
- 9) Puchta H (1998) **Trends in Plant Sci.** 3: 77-78.
- 10) Risseuw E, Franke-van Dijk MEI and Hooykaas PJJ (1997) **Plant J.** 11: 717-728.
- 11) Stougaard J (1993) **Plant J.** 3: 755-761.
- 12) Sundaresan V. et al. (1995) **Genes and Dev.** 9: 1797-1810.
- 15) 13) Thykjaer T, Finnemann J, Schausser L, Christensen L, Poulsen C and Stougaard J (1997) **Plant Mol. Biol.** 35: 523-530.
- 14) Walden R, Fritze K, Hayashi H, Miklashevichs E, Harling H and Schell J (1994) **Plant Mol. Biol.** 26: 1521-1528.
- 20) 15) Matsuhara S, Jingu F, Takahashi T, Komeda Y (2000) **Plant J.** 22: 79-86.

25           The present invention is not limited to the embodiments described and exemplified above, but is capable of variation and modification without departure from the scope of the appended claims.



3. The DNA construct of claim 1, wherein the  
5 termini comprise *Agrobacterium* tDNA left and right  
borders.

15                    5. The DNA construct of claim 4, wherein the  
DNA substrate for a selected transposase is a maize *Ds*  
element and the selected transposase is a maize *Ac*-  
dependent transposase.

7. The DNA construct of claim 1, wherein the  
25 positive selection gene confers resistance to a selection  
agent selected from the group consisting of antibiotics  
and herbicides.

9. The DNA construct of claim 1, wherein the negative selection gene encodes a gene product that converts an innocuous substance to a substance that is

deleterious or lethal to the cells.

10. The DNA construct of claim 9, wherein the negative selection gene is a *CodA* gene.

5

11. The DNA construct of claim 1, wherein the detectable marker gene encodes a detectable gene product selected from the group consisting of:  $\beta$ -glucuronidase,  $\beta$ -galactosidase, chloramphenicol acetyl transferase, 10 luciferase, green fluorescent protein, alcohol dehydrogenase and a transcription factor.

12. The DNA construct of claim 11, wherein the detectable marker gene encodes  $\beta$ -glucuronidase.

15

13. The DNA construct of claim 1, wherein the termini comprise *Agrobacterium* tDNA right and left borders, the DNA substrate for a selected transposase comprises *Ds* substrates for a maize *Ac*-dependent 20 transposase, the positive selection gene encodes phosphinothricin acetyltransferase, the negative selection gene encodes cytosine deaminase, the detectable marker gene encodes  $\beta$ -glucuronidase and the first and second cloning sites are polylinker sequences.

25

14. The DNA construct of claim 1 wherein one or more of the positive selection gene, negative selection gene and detectable marker gene is a chimeric gene comprising a coding sequence operably linked to one 30 or more heterologous promoters.

15. The DNA construct of claim 14, wherein the promoter is selected from the group consisting of constitutive promoters, inducible promoters and tissue-specific promoters. 35



- 31 -

16. The DNA construct of claim 14, wherein the chimeric gene comprises a plurality of promoters.

17. The DNA construct of claim 14, wherein the  
5 promoter is a cauliflower mosaic virus 35S promoter.

18. The DNA construct of claim 1, which comprises additional cloning sites disposed between the first cloning site and the second cloning site for  
10 insertion of one or more additional DNA segments, the additional cloning site being disposed relative to the positive selection gene so as not to interfere with the conferring of the selectable phenotype.

15                    19. The DNA construct of claim 1, wherein the detectable marker gene in its entirety is disposed between one of the DNA substrates for a selected transposase and the terminus closest thereto.

20                   20. The DNA construct of claim 1, wherein one  
of the DNA substrates for a selected transposase is  
located within the detectable marker gene in a manner  
that does not disrupt operability of the detectable  
marker gene unless the DNA substrate is acted upon by the  
25 selected transposase.

21. The DNA construct of claim 20, wherein the one of the DNA substrates for a selected transposase is located between the promoter and the coding sequence of the detectable marker gene.

22. The DNA construct of claim 1, operably inserted into a vector for transforming a cell.

35            23. The DNA construct of claim 22, wherein the

cell is a plant cell and the vector is an *Agrobacterium* vector.

24. The DNA construct of claim 1, adapted for  
5 integrating a heterologous DNA segment at a pre-  
determined location of a genome, wherein the adaptation  
comprises inserting a first targeting segment in the  
first cloning site and a second targeting segment in the  
second cloning site, each targeting segment comprising a  
10 DNA sequence substantially homologous to sequences in the  
genome comprising or flanking the pre-determined  
location, the targeting segments enabling the DNA  
construct to integrate into the genome at the pre-  
determined location by homologous recombination.

25. A method for inserting a heterologous DNA molecule into a pre-determined location on a plant genome, which comprises:

a) transforming a sample of plant cells  
20 containing the genome with the DNA construct of claim 24,  
to produce a substrate-transformed cell line;

b) transforming an equivalent sample of plant cells with a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct of claim 24, to produce a transposase-transformed cell line;

b) regenerating fertile organisms from each of the transformed cell lines;

30 c) crossing the substrate-transformed line  
with the transposase-transformed line to produce F1  
progeny;

d) self-pollinating the F1 progeny to produce F2 progeny; and

e) growing the F2 progeny in the presence  
35 of the positive selection agent and the negative

- 33 -

selection agent, progeny plants comprising the heterologous DNA inserted into the pre-determined location on the plant's genome being capable of surviving in the presence of both the positive selection agent and the negative selection agent.

26. The method of claim 26, which further comprises selecting a substrate-transformed cell line comprising one copy of the DNA construct per cell.

27. A kit for inserting a heterologous DNA molecule into a pre-determined location on a plant genome, which comprises a container containing the DNA construct of claim 24 and instructions for using the DNA construct to insert a heterologous DNA molecule into a pre-determined location on a plant genome.

28. The kit of claim 27, which further comprises a DNA construct having a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct of claim 27.

29. A method for activation tagging of a plant genome to create variants displaying a desired phenotype, which comprises:

a) transforming a sample of plant cells containing the genome with the DNA construct of claim 1 or claim 24, to produce a substrate-transformed cell line;

b) transforming an equivalent sample of plant cells with a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct of claim 1, to produce a transposase-transformed cell line;

b) regenerating fertile organisms from

- 34 -

each of the transformed cell lines;

c) crossing the substrate-transformed line with the transposase-transformed line to produce F1 progeny;

5 d) self-pollinating the F1 progeny to produce F2 progeny; and

e) growing the F2 progeny under conditions pre-determined to select for the desired phenotype in the plant.

10

30. The method of claim 29, wherein in the DNA construct, the one of the DNA substrates for a selected transposase most proximal to the 3' end of the construct is located between the promoter and the coding sequence of the detectable marker gene.

15

31. A kit for activation tagging of a plant genome to create variants displaying a desired phenotype, which comprises the DNA construct of claim 1 or claim 24, and instructions for using the construct to perform the activation tagging.

20

32. The kit of claim 32, which further comprises a DNA construct having a gene encoding a transposase that specifically acts on the DNA substrates in the DNA construct of claim 31.

25

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
14 December 2000 (14.12.2000)

PCT


(10) International Publication Number  
WO 00/75289 A1

- (51) International Patent Classification<sup>7</sup>: C12N 5/04, 15/09, 15/63, 15/65, 15/82, 15/84, 15/87, A01H 1/00, 5/00, 5/10
- (74) Agents: REED, Janet, E. et al.; Saul Ewing Remick & Saul LLP, Centre Square West, 38th Floor, 1500 Market Street, Philadelphia, PA 19102-2186 (US).
- (21) International Application Number: PCT/US00/15783
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 8 June 2000 (08.06.2000)
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/138,968 8 June 1999 (08.06.1999) US
- (71) Applicant (*for all designated States except US*): RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US/US); Old Queens, Somerset Street, New Brunswick, NJ 08903 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): LAM, Eric (US/US); 19 Corona Road, East Brunswick, NJ 08816 (US).

## Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/75289 A1

(54) Title: COMPOSITIONS AND METHODS FOR TARGETED GENE INSERTION

(57) Abstract: DNA constructs and methods for targeted integration of heterologous genes into a genome are disclosed. A transposon/transposase system is used to generate the substrates for homologous recombination in transgenic organisms. Targeted integration is selected in progeny using a combination of positive and negative selection markers. By eliminating the negative selection, the constructs and methods are adaptable for performing activation tagging, which relies on random integration events.



Figure 1




Figure 2

Docket No.

RU-0175

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

### Compositions and Methods for Targeted Gene Insertion

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 8 June 2000 as United States Application No. or PCT International

Application Number PCT/US00/15783

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐



60/138,068

**June 8, 1999**

(Filing Date)

(Filing Date)

(Filing Date)


(Filing Date)

(Filing Date)

(Filing Date)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



Send Correspondence to:

Direct Telephone Calls to: *(name and telephone number)*

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor <b>Eric Lam</b>		Date <i>Jan. 17, 2002</i>
Sole or first inventor's signature <i>[Signature]</i>		
Residence <b>East Brunswick, New Jersey</b> <i>NY</i>		
Citizenship <b>US</b>		
Post Office Address <b>19 Corona Road</b>		
<b>East Brunswick, New Jersey 08816</b>		

Full name of second inventor, if any	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	